Multiple Sclerosis Clinical Trials in Ohio

20 recruiting studies across 2 cities

Browse by City

All Trials in Ohio

Phase

Trial	Phase	Sponsor	Dist.
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy	Phase 1/2	UniQure Biopharma B.V.	<1 mi
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)	—	TG Therapeutics, Inc.	<1 mi
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders	Phase 1	TG Therapeutics, Inc.	<1 mi
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis	Phase 3	Sanofi	<1 mi
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.	Phase 3	Novartis Pharmaceuticals	<1 mi
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)	Phase 3	Amgen	<1 mi
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis	Phase 3	Sanofi	<1 mi
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis	Phase 2	Novartis Pharmaceuticals	<1 mi
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity	Phase 2	Celgene	<1 mi
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer	Phase 1	National Cancer Institute (NCI)	<1 mi
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses	Phase 2	Reunion Neuroscience Inc	<1 mi
TSC Biosample Repository and Natural History Database	—	National Tuberous Sclerosis Association	<1 mi
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis	Phase 1	AstraZeneca	<1 mi
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)	Phase 1	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	<1 mi
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis	N/A	Cionic, Inc.	<1 mi
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab	Phase 3	TG Therapeutics, Inc.	<1 mi
Care in Multiple Sclerosis (MS)	—	NYU Langone Health	<1 mi
Central Vein Sign in Multiple Sclerosis Extension Study	N/A	The Cleveland Clinic	<1 mi
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod	Phase 4	University of Colorado, Denver	<1 mi
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)	Phase 3	National Institute of Allergy and Infectious Diseases (NIAID)	<1 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.